Gwang-Cheol Park
Amministratore Delegato presso Premierbio Co., Ltd.
Profilo
Gwang-Cheol Park is currently the Chief Executive Officer at Premierbio Co., Ltd.
Prior to this, he was the Chairman & Co-Chief Executive Officer at DSK Co., Ltd.
and an Independent Director at KB Securities Co., Ltd.
He received his undergraduate, graduate, and doctorate degrees from Konkuk University.
Posizioni attive di Gwang-Cheol Park
| Società | Posizione | Inizio |
|---|---|---|
Premierbio Co., Ltd.
 Premierbio Co., Ltd. Pharmaceuticals: OtherHealth Technology Premierbio Co., Ltd. is engaged in developing Protoxin. It offers development and supply of Botulinum type A Toxin. The company was founded on September 25, 2015 and is headquartered in Anseong, South Korea. | Amministratore Delegato | - |
Precedenti posizioni note di Gwang-Cheol Park
| Società | Posizione | Fine |
|---|---|---|
| DSK CO., LTD. | Amministratore Delegato | - |
| HYUNDAI SECURITIES CO LTD | Direttore/Membro del Consiglio | - |
Formazione di Gwang-Cheol Park
| Konkuk University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| DSK CO., LTD. | Electronic Technology |
| Aziende private | 2 |
|---|---|
KB Securities Co., Ltd
 KB Securities Co., Ltd Investment ManagersFinance KB Securities Co., Ltd (KB Securities) is a private equity subsidiary of KB Financial Group, Inc. founded in 1962. The firm is headquartered in Seoul, South Korea. | Finance |
Premierbio Co., Ltd.
Premierbio Co., Ltd. Pharmaceuticals: OtherHealth Technology Premierbio Co., Ltd. is engaged in developing Protoxin. It offers development and supply of Botulinum type A Toxin. The company was founded on September 25, 2015 and is headquartered in Anseong, South Korea. | Health Technology |
- Borsa valori
- Insiders
- Gwang-Cheol Park
